Abstract
Genetic and biochemical evidence continues to implicate the production and accumulation of the Aβ42 peptide as the causative factor in Alzheimers disease (AD). Thus, a variety of strategies have been developed to decrease the production and/or aggregation of this peptide, which may be clinically useful for the treatment of this devastating disorder. Recently, the discovery that some non-steroidal anti-inflammatory drugs (NSAIDs) appear to selectively decrease the production of Aβ42 has opened a novel therapeutic avenue for AD treatment that may circumvent potential toxicity associated with long-term global inhibition of γ-secretase activity. One drug from this class of compounds, R-flurbiprofen, has advanced to phase 3 clinical trials and may soon provide insight into the viability of this strategy for the prevention or treatment of AD. Delineating the target and mechanism of these compounds is essential for developing new agents with increased potency and optimized pharmacologic properties. The evidence indicating that these chemicals modulate the production of Aβ peptides by directly interacting with the γ-secretase complex is summarized.
Current Topics in Medicinal Chemistry
Title: Possible Mechanisms of Action of NSAIDs and Related Compounds that Modulate γ - Secretase Cleavage
Volume: 8 Issue: 1
Author(s): Thomas Kukar and Todd E. Golde
Affiliation:
Abstract: Genetic and biochemical evidence continues to implicate the production and accumulation of the Aβ42 peptide as the causative factor in Alzheimers disease (AD). Thus, a variety of strategies have been developed to decrease the production and/or aggregation of this peptide, which may be clinically useful for the treatment of this devastating disorder. Recently, the discovery that some non-steroidal anti-inflammatory drugs (NSAIDs) appear to selectively decrease the production of Aβ42 has opened a novel therapeutic avenue for AD treatment that may circumvent potential toxicity associated with long-term global inhibition of γ-secretase activity. One drug from this class of compounds, R-flurbiprofen, has advanced to phase 3 clinical trials and may soon provide insight into the viability of this strategy for the prevention or treatment of AD. Delineating the target and mechanism of these compounds is essential for developing new agents with increased potency and optimized pharmacologic properties. The evidence indicating that these chemicals modulate the production of Aβ peptides by directly interacting with the γ-secretase complex is summarized.
Export Options
About this article
Cite this article as:
Kukar Thomas and Golde E. Todd, Possible Mechanisms of Action of NSAIDs and Related Compounds that Modulate γ - Secretase Cleavage, Current Topics in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/156802608783334042
DOI https://dx.doi.org/10.2174/156802608783334042 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Progresses of Novel Natural Products and Their Derivatives/ Analogs as Anti-Alzheimer Candidates: an Update
Mini-Reviews in Medicinal Chemistry Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications
Current Gene Therapy Potential Roles of Selenium and Selenoproteins in the Prevention of Alzheimer's Disease
Current Topics in Medicinal Chemistry Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies
Current Topics in Medicinal Chemistry Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Discovery of Anti-Alzheimer Agents: Current Ligand-Based Approaches toward the Design of Acetylcholinesterase Inhibitors
Mini-Reviews in Medicinal Chemistry Environment and Neurodegenerative Diseases: An Update on miRNA Role
MicroRNA Recent Patents in Dendrimers for Nanomedicine: Evolution 2014
Recent Patents on Nanomedicine Pharmacological Approaches of Alzheimer's Disease: An Update
Current Drug Therapy Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets New Targets for Therapy in Polyglutamine (polyQ) Expansion Diseases
Current Drug Therapy Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Modelling and Treating Amyotrophic Lateral Sclerosis through Induced- Pluripotent Stem Cells Technology
Current Stem Cell Research & Therapy Nicotinic Receptors Containing the α7 Subunit: A Model for Rational Drug Design
Current Medicinal Chemistry Inhibitors of Myostatin- and Proteasome-Dependent Signaling for Attenuating Muscle Wasting
Recent Patents on Regenerative Medicine Activation of Brain Endothelium by Soluble Aggregates of the Amyloid-β Protein Involves Nuclear Factor-κB
Current Alzheimer Research Meet Our Editorial Board Member
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Xanthone: Potential Acetylcholinesterase Inhibitor for Alzheimer's Disease Treatment
Mini-Reviews in Medicinal Chemistry Relevance of the Chronobiological and Non-chronobiological Actions of Melatonin for Enhancing Therapeutic Efficacy in Neurodegenerative Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial [Hot Topic: Mitochondria as a Pharmacological Target: A Clue for Efficacy and a Reason for Toxicity (Executive Guest Editor: Nadezda Apostolova)]
Current Pharmaceutical Design